Newsroom - Page 5

The suit comes after Mylan has already faced hearing in Congress and investigations from the US Department of Justice and the Federal Trade Commission.
The 2017 National Health Security Preparedness Index, released by the Robert Wood Johnson Foundation, indicates that the United States is slowly becoming more prepared to handle public health catastrophes, but some states are still lagging behind.
A study in Journal of Medical Internet Research sought to discover how technologies could encourage daily walking in this population. The researchers developed 3 prototype apps using different persuasive technology design principles: dialogue support, primary task support, and social support.
The most common modifiable behavioral risk factors identified in the study are all treatable, suggesting that prevention could go a long way toward reducing their impact.
The University of Connecticut has initiated recruitment for a phase I trial to test the safety and efficacy of OncoImmunome, a personalized vaccine designed to prevent relapse in patients diagnosed with Stage III or IV ovarian cancer.
By understanding the biology of myeloma tumor cells, researchers can better develop therapies, including drug combinations, that target the complex mechanisms at play in the disease, according to Shaji Kumar, MD, professor of medicine at the Mayo Clinic.
A second biosimilar to infliximab, marketed as Remicade by Johnson & Johnson, has received FDA approval. Infliximab-abda (Renflexis) was developed by Samsung Bioepis/Merck and has been approved for multiple indications.
Clinical Pathways Compendium
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium